Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in MPN-associated Myelofibrosis and Anemia
NCT03194542Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2017
- Primary completion
- Jul 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, open-label trial of luspatercept in anemia (4 cohorts), sponsored by Celgene Corporation. Primary endpoint: Number of Participants With Anemia Responses Over Any 84-Day Period. Started Nov 2017; status: completed.
02
Drugs
luspatercept
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03194542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194542.